For the estimated 250,000 people worldwide living with achondroplasia, the most common form of short-limbed dwarfism, treatment options have historically been limited to growth hormone and surgical interventions with modest or variable outcomes. A rigorous Phase 3 trial now adds a compelling new chapter: a once-daily oral pill targeting the root molecular cause of the condition produced statistically significant gains in growth velocity within a single year.
The multicenter, double-blind, placebo-controlled trial enrolled 114 children aged 3 to 17 with confirmed achondroplasia, randomizing them 2:1 to either infigratinib at 0.25 mg/kg daily or placebo for 52 weeks. Infigratinib selectively inhibits FGFR1-3 tyrosine kinase activity, directly counteracting the hyperactive FGFR3 signaling that drives suppressed endochondral bone growth in this condition. At week 52, the infigratinib group showed a least-squares mean annualized height velocity advantage of 1.74 cm per year over placebo (95% CI: 1.31–2.17; P<0.001), alongside a meaningful improvement in height z-score of +0.32. The upper-to-lower body segment ratio, a proxy for skeletal proportionality, did not show statistically significant improvement.
This trial deserves careful contextualization. Achondroplasia treatment entered a new era in 2021 when vosoritide, a CNP analogue delivered via daily subcutaneous injection, received FDA approval. Infigratinib now offers a mechanistically distinct, orally administered alternative — a significant practical advantage for pediatric adherence and quality of life. The effect size of roughly 1.7 cm/year in annualized height velocity is comparable to vosoritide's reported gains in its pivotal trial, suggesting broadly similar efficacy through different molecular routes. However, long-term skeletal proportionality, neurological outcomes such as foramen magnum compression risk, and durability of effect beyond 52 weeks remain open questions. The trial's modest sample size and single-year follow-up warrant extension studies before drawing conclusions about lifetime growth trajectory or safety. Nonetheless, a well-powered, placebo-controlled Phase 3 result in this population represents a genuinely important advance — not merely incremental.